SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported) October
5, 2006
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01. Regulation FD Disclosures.
On
October 5, 2006 the Registrant issued the press release titled “Chembio to Host
Conference Call to Discuss Marketing Partner Agreements for Rapid HIV
Tests”
included herein as Exhibit 99.1.
ITEM
9.01. Financial Statements and Exhibits
(d) Exhibits.
|
99.1
|
Press
Release titled “Chembio to Host
Conference Call to Discuss Marketing Partner Agreements for
Rapid HIV
Tests” issued October 5, 2006.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned
thereunto
duly authorized.
Date:
October
5, 2006 Chembio
Diagnostics, Inc.
By: /s/
Lawrence A. Siebert
Lawrence
A. Siebert
Chief
Executive Officer
Exhibit
99.1 Press Release
Chembio
to Host Conference Call to Discuss
Marketing
Partner Agreements for Rapid HIV Tests
NEW
YORK--(BUSINESS WIRE)--October. 5, 2006--Chembio Diagnostics, Inc.
(OTCBB:CEMI
-
News)
will
host a conference call on Tuesday, October 10th
at
4:30pm EST. The call will be held to discuss the marketing partner
agreements,
for their rapid HIV tests, and financing that was announced earlier
today. A
live web cast can be accessed by clicking on the following link http://www.vcall.com/IC/CEPage.asp?ID=109970. A
recording of this web cast can also be accessed using the same
link.
ABOUT
CHEMBIO
Chembio
Diagnostics, Inc., a developer and manufacturer of rapid diagnostic
tests for
infectious diseases, is on the frontlines of the global battle against
the AIDS
pandemic. The Company has received marketing approval from the FDA
for its SURE
CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests. The Company
also
manufactures rapid tests for veterinary Tuberculosis and Chagas Disease,
and has
developed a patent-pending technology, the Dual Path Platform (DPP(TM)),
for its
next generation HIV and other rapid tests. For additional information
please
visit www.chembio.com.
FORWARD-LOOKING
STATEMENTS
Statements
contained herein that are not historical facts may be forward-looking
statements
within the meaning of the Securities Act of 1933, as amended. Forward-looking
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements are
estimates
only, as the Company has not completed the preparation of its financial
statements for those periods, nor has its auditor completed the audit
of those
results. Actual revenue may differ materially from those anticipated
in this
press release. Such statements reflect management's current views,
are based on
certain assumptions and involve risks and uncertainties. Actual results,
events,
or performance may differ materially from the above forward-looking
statements
due to a number of important factors, and will be dependent upon
a variety of
factors, including, but not limited to Chembio's ability to obtain
additional
financing, to obtain regulatory approvals in a timely manner, and
the demand for
Chembio's products. Chembio undertakes no obligation to publicly
update these
forward-looking statements to reflect events or circumstances that
occur after
the date hereof or to reflect any change in Chembio's expectations
with regard
to these forward-looking statements or the occurrence of unanticipated
events.
Factors that may impact Chembio's success are more fully disclosed
in Chembio's
most recent public filings with the U.S. Securities and Exchange
Commission.
Contact:
The
Investor Relations Group
Investors:
James
Carbonara, 212-825-3210
or
Media:
Susan
Morgenbesser, 212-825-3210
Source:
Chembio Diagnostics, Inc.